Skip to main content
OpenTrials
Completed

NCT Number: NCT01684176

Tailored Intervention to Improve Patient Adherence to Secondary Stroke Prevention Medication

Patient suffering a Transient Ischemic Attack (TIA) or stroke are subsequently at high risk of a new stroke, however, poor adherence to secondary prevention medications occurs frequently within this patient group. The purpose of this study is to evaluate whether a complex tailored pharmacist intervention will lead to increased adherence to secondary stroke prevention medications and less new stroke events when compared to a usual care group. Interventions focus on motivational interviewing, medication review and telephone follow up.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Stroke Behavior Brain Diseases Brain Ischemia Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Health Behavior Ischemic Attack, Transient Medication Adherence Nervous System Diseases Patient Acceptance of Health Care Patient Compliance Transient Ischemic Attack Treatment Adherence and Compliance Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Odense University Hospital

Odense C, 5000, Denmark

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age: 18 years or older
  • Patient admitted or receiving ambulatory treatment for an acute transient ischemic attack or ischemic stroke which has occurred within the previous 30 days.
  • The patient or a carer usually dispenses the patient's medications
  • Written consent

Exclusion criteria

  • Cognitive or physical impairment that would preclude comprehension of a conversation
  • Terminal illness
  • Lives in a care home or an institution
  • Receives dose dispensed medicine from a pharmacy
  • Medicine is dispensed by a nurse in the patient's home
  • Correctional mental health patients

Treatment and study plan

Complex tailored intervention

Behavioral

Usual Care

Behavioral

Primary outcomes

  1. Medication Adherence to antiplatelets, anticoagulants and statins measured by proportion of days covered (PDC).

    Time frame: One year from inclusion

  2. For antiplatelets, anticoagulants and statins: Percent of patients that are at least 80% adherent (PDC>0.8)

    Time frame: 1 year from inclusion

Secondary outcomes

  1. Medication Adherence to antihypertensives measured by proportion of days covered (PDC)

    Time frame: One year from inclusion

  2. Percent of patients that are at least 80% adherent (PDC>0.8) to antihypertensives

    Time frame: One year from inclusion

  3. Non-persistence with thromboprophylactic agents ( antiplatelets, anticoagulants, statins and antihypertensives) measured by percent of patients that are not supplied with medication for more than 3 continuous months

    Time frame: One year from inclusion

  4. Accept rate for thromboprophylactic agents measured by percent of patients starting treatment within 0-90 days after discharge.

    Time frame: 3 months from discharge

  5. Composite endpoint: stroke, myocardial infarction or cardiovascular death

    Time frame: One year from inclusion

Sponsors and collaborators

Lead sponsor

Odense University Hospital

Other

Collaborators

  • University of Southern Denmark

Registry information

Official study title

Pharmacist Intervention Programme to Improve Medication Adherence in Stroke Patients

Important dates

Study start
2012
Primary completion
2013
Study completion
2014
First posted
Sep 12, 2012
Registry last updated
Jan 21, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.